Progress towards the clinical use of CD3 monoclonal antibodies in the treatment of autoimmunity

Current Opinion in Organ Transplantation

Volumn 14, Issue 4, 2009, Pages 351-356

  Chatenoud, Lucienne ^a,b  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

Autoimmunity; CD3 antibodies; Immune therapy; Immune tolerance; Transplantation

Indexed keywords

INSULIN; MONOCLONAL ANTIBODY CD3; OKT 3; PLACEBO; T LYMPHOCYTE RECEPTOR;

AUTOIMMUNE DISEASE; CLINICAL TRIAL; DISEASE COURSE; GRAFT REJECTION; HERPES VIRUS INFECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; NONHUMAN; ORGAN TRANSPLANTATION; PANCREAS ISLET CELL FUNCTION; REVIEW; TREATMENT OUTCOME;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD3; AUTOIMMUNE DISEASES; AUTOIMMUNITY; CHRONIC DISEASE; DIABETES MELLITUS, TYPE 1; DISEASE MODELS, ANIMAL; GRAFT REJECTION; HUMANS; IMMUNE TOLERANCE; IMMUNOSUPPRESSIVE AGENTS; MICE; TRANSPLANTATION TOLERANCE; TREATMENT OUTCOME;

EID: 68849130127     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0b013e32832ce95a     Document Type: Review

References (60)

1. Sprent J, Kishimoto H. The thymus and negative selection. Immunol Rev 2002; 185:126-135.
2. Peterson P, Org T, Rebane A. Transcriptional regulation by AIRE: molecular mechanisms of central tolerance. Nat Rev Immunol 2008; 8:948-957.
3. Goodnow CC, Sprent J, Fazekas de St Groth B, Vinuesa CG. Cellular and genetic mechanisms of self tolerance and autoimmunity. Nature 2005; 435:590-597. (Pubitemid 40825498)
4. Goodnow CC. Multistep pathogenesis of autoimmune disease. Cell 2007; 130:25-35.
5. Ohashi PS, Oehen S, Buerki K, et al. Ablation of 'tolerance' and induction of diabetes by virus infection in viral antigen transgenic mice. Cell 1991; 65:305-317. (Pubitemid 121006060)
6. Lang KS, Recher M, Junt T, et al. Toll-like receptor engagement converts T-cell autoreactivity into overt autoimmune disease. Nat Med 2005; 11:138-145. (Pubitemid 40321348)
7. Rocha B, Von Boehmer H. Peripheral selection of the T cell repertoire. Science 1991; 251:1225-1228.
8. Schwartz RH. A cell culture model for T lymphocyte clonal anergy. Science 1990; 248:1349-1356. (Pubitemid 20208185)
9. Mosmann TR, Coffman RL. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 1989; 7:145-173.
10. Gershon RK, Kondo K. Infectious immunological tolerance. Immunology 1971; 21:903-914.
11. Qin S, Cobbold SP, Pope H, et al. 'Infectious' transplantation tolerance. Science 1993; 259:974-977.
12. Cobbold SP, Nolan KF, Graca L, et al. Regulatory T cells and dendritic cells in transplantation tolerance: molecular markers and mechanisms. Immunol Rev 2003; 196:109-124. (Pubitemid 37468107)
13. Sakaguchi S. Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and nonself. Nat Immunol 2005; 6:345-352. (Pubitemid 41716771)
14. Bach JF. The effect of infections on susceptibility to autoimmune and allergic diseases. N Engl J Med 2002; 347:911-920.
15. Makino S, Kunimoto K, Muraoka Y, et al. Breeding of a nonobese, diabetic strain of mice. Exp Anim 1980; 29:1-13. (Pubitemid 10185796)
16. Bach JF. Insulin-dependent diabetes mellitus as an autoimmune disease. Endocrine Rev 1994; 15:516-542. (Pubitemid 24271242)
17. Serreze DV, Chapman HD, Varnum DS, et al. B lymphocytes are essential for the initiation of T cell-mediated autoimmune diabetes: analysis of a new 'speed congenic' stock of NOD.Ig mu(null) mice. J Exp Med 1996; 184: 2049-2053.
18. Wicker LS, Miller BJ, Mullen Y. Transfer of autoimmune diabetes mellitus with splenocytes from nonobese diabetic (NOD) mice. Diabetes 1986; 35:855-860. (Pubitemid 16014435)
19. You S, Belghith M, Cobbold S, et al. Autoimmune diabetes onset results from qualitative rather than quantitative age-dependent changes in pathogenic T-cells. Diabetes 2005; 54:1415-1422. (Pubitemid 40586672)
20. Boitard C, Yasunami R, Dardenne M, Bach JF. T cell-mediated inhibition of the transfer of autoimmune diabetes in NOD mice. J Exp Med 1989; 169:1669-1680. (Pubitemid 19126824)
21. You S, Leforban B, Garcia C, et al. Adaptive TGF-{beta}-dependent regulatory T cells control autoimmune diabetes and are a privileged target of anti-CD3 antibody treatment. Proc Natl Acad Sci U S A 2007; 104:6335-6340. (Pubitemid 47186095)
22. Salomon B, Lenschow DJ, Rhee L, et al. B7/CD28 Costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes. Immunity 2000; 12:431-440. (Pubitemid 30953967)
23. Chatenoud L, Primo J, Bach JF. CD3 antibody-induced dominant self tolerance in overtly diabetic NOD mice. J Immunol 1997; 158:2947-2954. (Pubitemid 127470558)
24. Chatenoud L, Thervet E, Primo J, Bach JF. Anti-CD3 antibody induces longterm remission of overt autoimmunity in nonobese diabetic mice. Proc Natl Acad Sci U S A 1994; 91:123-127. (Pubitemid 24018655)
25. Chatenoud L. CD3-specific antibody-induced active tolerance: from bench to bedside. Nat Rev Immunol 2003; 3:123-132. (Pubitemid 37328690)
26. Kohm AP, Williams JS, Bickford AL, et al. Treatment with nonmitogenic anti- CD3 monoclonal antibody induces CD4+ T cell unresponsiveness and functional reversal of established experimental autoimmune encephalomyelitis. J Immunol 2005; 174:4525-4534. (Pubitemid 40504531)
27. Perruche S, Zhang P, Liu Y, et al. CD3-specific antibody-induced immune tolerance involves transforming growth factor-beta from phagocytes digesting apoptotic T cells. Nat Med 2008; 14:528-535. This interesting manuscript is the second report extending the results initially obtained in the NOD mouse to the EAE model. The works point to the key role of TGF-b produced by macrophages in the therapeutic effect of CD3 antibodies. (Pubitemid 351655213)
28. Ludviksson BR, Ehrhardt RO, Strober W. TGF-beta production regulates the development of the 2,4,6-trinitrophenol-conjugated keyhole limpet hemocyanin-induced colonic inflammation in IL-2-deficient mice. J Immunol 1997; 159:3622-3628.
29. Chatenoud L, Baudrihaye MF, Kreis H, et al. Human in vivo antigenic modulation induced by the anti-T cell OKT3 monoclonal antibody. Eur J Immunol 1982; 12:979-982. (Pubitemid 13203591)
30. Belghith M, Bluestone JA, Barriot S, et al. TGF-beta-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes. Nat Med 2003; 9:1202-1208. First detailed mechanistic analysis of the immune mechanisms underlying the longterm effect of CD3 antibodies. Results highlight the central role of TGF-b in the tolerance-promoting ability of the antibody. (Pubitemid 37173706)
31. You S, Thieblemont N, Alyanakian MA, et al. Transforming growth factor-beta and T-cell-mediated immunoregulation in the control of autoimmune diabetes. Immunol Rev 2006; 212:185-202. (Pubitemid 44116709)
32. Cosimi AB, Colvin RB, Burton RC, et al. Use of monoclonal antibodies to Tcell subsets for immunologic monitoring and treatment in recipients of renal allografts. N Engl J Med 1981; 305:308-314.
33. Ortho Multicenter Transplant Study Group. A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants. N Engl J Med 1985; 313:337-342.
34. Cosimi AB, Burton RC, Colvin RB, et al. Treatment of acute renal allograft rejection withOKT3monoclonal antibody. Transplantation 1981;32:535-539. (Pubitemid 12204717)
35. Chatenoud L, Baudrihaye MF, Chkoff N, et al. Restriction of the human in vivo immune response against the mouse monoclonal antibody OKT3. J Immunol 1986; 137:830-838. (Pubitemid 16072022)
36. Chatenoud L, Ferran C, Reuter A, et al. Systemic reaction to the anti-T-cell monoclonal antibody OKT3 in relation to serum levels of tumor necrosis factor and interferon-gamma. N Engl J Med 1989; 320:1420-1421. (Pubitemid 19138943)
37. Abramowicz D, Schandene L, Goldman M, et al. Release of tumor necrosis factor, interleukin-2, and gamma-interferon in serum after injection of OKT3 monoclonal antibody in kidney transplant recipients. Transplantation 1989; 47:606-608. (Pubitemid 19110914)
38. Alegre ML, Peterson LJ, Xu D, et al. A nonactivating 'humanized' anti-CD3 monoclonal antibody retains immunosuppressive properties in vivo. Transplantation 1994; 57:1537-1543.
39. Bolt S, Routledge E, Lloyd I, et al. The generation of a humanized, nonmitogenic CD3 monoclonal antibody which retains in vitro immunosuppressive properties. Eur J Immunol 1993; 23:403-411. (Pubitemid 23075070)
40. Smith JA, Tang Q, Bluestone JA. Partial TCR signals delivered by FcRnonbinding anti-CD3 monoclonal antibodies differentially regulate individual Th subsets. J Immunol 1998; 160:4841-4849. (Pubitemid 28215318)
41. Smith JA, Tso JY, Clark MR, et al. Nonmitogenic anti-CD3 monoclonal antibodies deliver a partial T cell receptor signal and induce clonal anergy. J Exp Med 1997; 185:1413-1422.
42. Xu D, Alegre ML, Varga SS, et al. In vitro characterization of five humanized OKT3 effector function variant antibodies. Cell Immunol 2000; 200:16-26.
43. Herold KC, Hagopian W, Auger JA, et al. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med 2002; 346:1692-1698. The first trial using the humanized OKT3 g1 Ala-Ala antibody to reverse ongoing disease in patients presenting recent onset type 1 diabetes. Both children and young adults were included in this study. (Pubitemid 34547482)
44. Herold KC, Gitelman SE, Masharani U, et al. A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in Cpeptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes. Diabetes 2005; 54:1763-1769. (Pubitemid 40770766)
45. Keymeulen B, Vandemeulebroucke E, Ziegler AG, et al. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med 2005; 352:2598-2608. The first multicentre placebo-controlled trial using the humanized ChAglyCD3 antibody to preserve b-cell mass in patients presenting recent onset type 1 diabetes. Only young adults and adult patients were included in this study. (Pubitemid 41007846)
46. Wajchenberg BL. {beta}-cell failure in diabetes and preservation by clinical treatment. Endocr Rev 2007; 28:187-218. (Pubitemid 46984834)
47. Sherry NA, Chen W, Kushner JA, et al. Exendin-4 improves reversal of diabetes in NOD mice treated with anti-CD3 monoclonal antibody by enhancing recovery of beta-cells. Endocrinology 2007; 148:5136-5144. (Pubitemid 350012634)
48. Chatenoud L, Bluestone JA. CD3-specific antibodies: a portal to the treatment of autoimmunity. Nat Rev Immunol 2007; 7:622-632. (Pubitemid 47123550)
49. Bresson D, Togher L, Rodrigo E, et al. Anti-CD3 and nasal proinsulin combination therapy enhances remission from recent-onset autoimmune diabetes by inducing Tregs. J Clin Invest 2006; 116:1371-1381. The first description in experimental mouse models of a combined treatment using CD3 antibody in association to a candidate b-cell autoantigen.
50. Serreze DV, Silveira PA. The role of B lymphocytes as key antigen-presenting cells in the development of T cell-mediated autoimmune type 1 diabetes. Curr Dir Autoimmun 2003; 6:212-227.
51. Hu CY, Rodriguez-Pinto D, Du W, et al. Treatment with CD20-specific antibody prevents and reverses autoimmune diabetes in mice. J Clin Invest 2007; 117:3857-3867. (Pubitemid 350224095)
52. Xiu Y, Wong CP, Bouaziz JD, et al. B lymphocyte depletion by CD20 monoclonal antibody prevents diabetes in nonobese diabetic mice despite isotype-specific differences in Fc gamma R effector functions. J Immunol 2008; 180:2863-2875.
53. Abrams JR, Lebwohl MG, Guzzo CA, et al. CTLA4Ig-mediated blockade of Tcell costimulation in patients with psoriasis vulgaris. J Clin Invest 1999; 103:1243-1252.
54. Abrams JR, Kelley SL, Hayes E, et al. Blockade of T lymphocyte costimulation with cytotoxic T lymphocyte-associated antigen 4-immunoglobulin (CTLA4Ig) reverses the cellular pathology of psoriatic plaques, including the activation of keratinocytes, dendritic cells, and endothelial cells. J Exp Med 2000; 192:681-694. (Pubitemid 30688797)
55. Genovese MC, Becker JC, Schiff M, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med 2005; 353:1114-1123. (Pubitemid 41317434)
56. Kremer JM, Westhovens R, Leon M, et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med 2003; 349:1907-1915. (Pubitemid 37409707)
57. Kremer JM, Dougados M, Emery P, et al. Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005; 52:2263-2271. (Pubitemid 41117408)
58. Mackie SL, Vital EM, Ponchel F, Emery P. Co-stimulatory blockade as therapy for rheumatoid arthritis. Curr Rheumatol Rep 2005; 7:400-406.
59. Shapiro AM, Lakey JR, Ryan EA, et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med 2000; 343:230-238.
60. Lakey JR, Kin T, Warnock GL, et al. Long-term graft function after allogeneic islet transplantation. Cell Transplant 2007; 16:441-446.